BioGenerator Ventures

IN10T Inc. is a digital agriculture company based in Chesterfield, Missouri, that specializes in developing internet-based platforms for agronomic field research and data analysis. Founded in 2016, IN10T focuses on addressing challenges related to farmer adoption of new technologies in agriculture. The company offers customized digital and data science solutions for clients in the agricultural sector, as well as for investors interested in agriculture. Additionally, IN10T provides agricultural field data analysis and farm testing services, aiming to enhance the efficiency and effectiveness of agricultural practices.

Solis Agrosciences, founded in 2021, is a plant science services company that focuses on accelerating research and development in crop innovation. The company offers advanced technology and research services tailored for Agtech companies, enabling them to rapidly test and develop new plant traits. Solis Agrosciences provides an end-to-end pipeline for gene-editing and transgenic plant generation and characterization. By supporting emerging startups within the biotechnology ecosystem, the company creates tools and services that facilitate scientific discovery and commercialization in the agricultural sector.

Peptyde Bio is an Agtech startup focused on developing bio-fungicidal technology to combat fungal diseases. The company specializes in natural antimicrobial peptides (AMPs) derived from plants, positioning itself as a key supplier in this niche market. By leveraging these innovative compounds, Peptyde Bio aims to provide more affordable and effective treatment options for patients suffering from fungal infections.

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

Buck Surgical provides surgical technologies that improve patient outcomes and expand access to care. Their patented coupling technology solves anastomotic failures with its novel and efficient method of performing anastomoses.

Impetus AG is engaged in the development of innovative insect control solutions that prioritize safety, effectiveness, and sustainability. The company specializes in creating bi-specific plant-based proteins designed to protect crops from harmful insects. Utilizing Bacillus thuringiensis technology, Impetus AG's products enhance crop yield by integrating antibodies within plant structures. This approach addresses the challenge of insect resistance that has emerged with existing commercial insect control products, offering farmers durable alternatives that support sustainable agriculture.

SentiAR, Inc. is a digital health company based in St. Louis, Missouri, specializing in 3D augmented reality solutions for interventional medical procedures. Founded in 2017 as a spin-off from Washington University, SentiAR has developed a platform that offers real-time holographic visualization of patients' anatomical structures and catheter locations. This technology integrates data from CT, MRI, and real-time mapping systems to create a controllable 3D holographic interface. The platform aims to enhance the delivery of care by allowing clinicians to visualize complex cardiac anatomy directly over the patient, thereby improving the treatment of cardiac arrhythmias during catheterization procedures. SentiAR is in the process of preparing its platform for submission to the FDA.

CuriMeta is a firm specializing in advanced real-world health data, primarily serving the life sciences sector. The company believes that health data generated within care systems possesses unique qualities that can significantly enhance medical research. CuriMeta curates and transforms data from various contributors into secure, de-identified, aggregated datasets that can be compliantly shared with researchers. This process aims to facilitate the discovery and development of new medical solutions. Committed to transparency and accountability, CuriMeta employs a joint governance committee to evaluate all data exchange requests, ensuring adherence to strict data security, patient privacy, and compliance standards. By accelerating the exchange of real-world health data, CuriMeta seeks to provide researchers with critical insights and evidence to address pressing scientific and clinical challenges, ultimately contributing to improved healthcare outcomes and the development of lifesaving cures.

Omniose is an early-stage biotechnology company focused on developing advanced conjugate vaccines to combat infectious diseases. The company specializes in pneumococcal conjugate vaccines, aiming to offer broader protection against various bacterial strains. Utilizing proprietary bioconjugation technology, Omniose's approach eliminates reliance on synthetic chemistry techniques, allowing for the generation of polysaccharide-protein conjugate-based vaccines targeting multiple pathogens, including respiratory infections caused by Streptococcus pneumoniae. This innovative platform enhances the ability of healthcare professionals to effectively treat patients by providing more comprehensive vaccine options.

Cadre Bioscience, LLC, founded in 2019 and located in Saint Louis, Missouri, focuses on developing therapeutics for various human diseases. The company is dedicated to accelerating the development of early-stage therapeutic assets by implementing a strategic plan that emphasizes de-risking and advancing these innovations. Cadre Bioscience aims to raise capital and attract skilled management to support its development initiatives, ultimately facilitating the commercialization of its technology to improve patient outcomes.

Healthy Bytes, Inc. develops a software platform that facilitates personalized nutritional counseling, connecting physicians, employers, and patients. Founded in 2014 and headquartered in Saint Louis, Missouri, with an additional office in New York, the company employs registered dietitians who provide consultations to employees seeking medical care for conditions such as obesity, diabetes, high blood pressure, and cardiovascular diseases. The platform enables users to book private consultations and allows dietitians to monitor their clients' eating habits. By leveraging existing medical benefits, employees can access nutritional counseling without incurring additional costs, promoting healthier lifestyles through expert dietary guidance.

Plastomics Inc. is a biotechnology company specializing in chloroplast genetic engineering to enhance crop performance. Founded in 2016 and based in St. Louis, Missouri, the company focuses on gene stacking and rapid breeding to improve yield production and nutritional quality. Its innovative technology platform allows for the precise insertion of beneficial traits into the chloroplasts of plant cells, facilitating the development of more effective biotech crops. This approach not only addresses current industry challenges but also eliminates cross-pollination, enabling clients to achieve trait expression in plants more reliably. Additionally, Plastomics' unique method of maternal inheritance streamlines breeding timelines and reduces costs, making it a valuable partner for seed companies in the agricultural sector.

Journeys Metabolic is a digital solution provider focused on metabolic care, specifically addressing obesity and Type 2 diabetes. The company offers a six-month, in-home program that integrates advanced technology, including AI-driven precision pathways and computer vision for food education, to facilitate sustained behavior modification. This HITRUST-compliant platform is designed to help health systems transition to value-based care without adding to the burden on care teams. By targeting insulin resistance and related chronic conditions, Journeys Metabolic supports shared savings optimization in metabolic diseases and nutrition-related disorders through tailored nutritional interventions. The program aims to improve patient outcomes by extending primary care into the home and fostering a fee-for-outcomes model in healthcare.

Aggio, LLC is an information technology company based in Saint Louis, Missouri, with an additional location in Madison, New Jersey. Founded in 2016, Aggio specializes in cloud-based sales applications tailored for the agriculture industry. The company's platform offers marketing and sales analytics that assist clients in making data-driven decisions through data harmonization and visualization. Aggio's software enables businesses to gain a comprehensive view of the market by integrating multiple data sources, facilitating effective engagement with customers and channel partners across both online and offline channels. This approach allows users to visualize and track key performance indicators, promoting faster decision-making processes.

KaloCyte, Inc. is a pre-clinical stage healthcare biotech company based in Baltimore, Maryland, founded in 2016. The company focuses on developing ErythroMer, a dried and bio-inspired artificial red blood cell intended to address life-threatening blood loss in situations where stored red blood cells are either unavailable or unsuitable for use. ErythroMer aims to provide context-dependent oxygen delivery while minimizing complications such as vasoconstriction and methemoglobin formation. This innovative approach seeks to enhance trauma care services by offering an effective alternative for managing traumatic hemorrhage when traditional blood supplies are inadequate.

Omniose is an early-stage biotechnology company focused on developing advanced conjugate vaccines to combat infectious diseases. The company specializes in pneumococcal conjugate vaccines, aiming to offer broader protection against various bacterial strains. Utilizing proprietary bioconjugation technology, Omniose's approach eliminates reliance on synthetic chemistry techniques, allowing for the generation of polysaccharide-protein conjugate-based vaccines targeting multiple pathogens, including respiratory infections caused by Streptococcus pneumoniae. This innovative platform enhances the ability of healthcare professionals to effectively treat patients by providing more comprehensive vaccine options.

Arch Innotek, LLC is a biotechnology company based in St. Louis, Missouri, focused on engineering microorganisms to produce natural ingredients that promote health for both humans and animals. Established in 2013, the company specializes in the fermentation of yeast to generate natural carotenoid antioxidants and other high-value molecules for the food, feed, pharmaceutical, and cosmetics industries. Arch Innotek employs sustainable and cost-effective fermentation processes to develop innovative technologies that provide healthier alternatives for consumers. Additionally, the company offers a range of scientific services, including HPLC analysis, LC-MS analysis, protein purification, and molecular cloning, to support its research and development efforts.

Start Right specializes in producing convenient, protein-rich breakfast foods designed to support a fit and active lifestyle. The company offers a range of products, including waffles, pancakes, and breakfast sliders, all crafted to be nutritious and flavorful. Their waffles are made with egg and dairy proteins, enriched with essential fiber, fruits, and vegetables, ensuring a wholesome meal. Additionally, Start Right’s products are gluten-free and contain no added sugar, making them suitable for health-conscious consumers seeking a quick and nutritious breakfast option.

Impetus AG is engaged in the development of innovative insect control solutions that prioritize safety, effectiveness, and sustainability. The company specializes in creating bi-specific plant-based proteins designed to protect crops from harmful insects. Utilizing Bacillus thuringiensis technology, Impetus AG's products enhance crop yield by integrating antibodies within plant structures. This approach addresses the challenge of insect resistance that has emerged with existing commercial insect control products, offering farmers durable alternatives that support sustainable agriculture.

BacterioScan, Inc. is a medical device company based in St. Louis, Missouri, focused on diagnosing and treating infectious diseases. The company has developed the 216Dx UTI System, which detects bacteria indicative of urinary tract infections (UTIs) in clinical urine samples and helps identify suitable antibiotic treatments. Additionally, BacterioScan offers the 216R Antibiotic Susceptibility Testing System, designed to detect bacterial infections, assess antibiotic resistance, and provide clinicians with tailored antimicrobial resistance profiles. Its precision bench-top systems facilitate rapid detection and real-time quantification of microbial growth, significantly enhancing laboratory efficiency compared to traditional plating methods. This innovative approach not only aids clinicians in personalizing patient care but also supports researchers in accelerating the development of new antibiotics. BacterioScan's technology aims to improve the quality of antibiotic therapy and mitigate the risks associated with antibiotic resistance.

Canopy Biosciences is a biotechnology company specializing in research tools for gene editing, molecular biology, and personalized medicine. Founded in 2016 and headquartered in St. Louis, Missouri, the company offers a range of products and services designed to enhance scientific discovery in biomedical research. Its gene editing technology, known as TUNR, facilitates targeted modifications in the genome by inserting polyA tracks into specific coding regions, which reduces mRNA levels and subsequently suppresses protein expression. This innovative approach supports researchers at universities, research institutions, and within the biotechnology and pharmaceutical sectors, advancing the fields of genetic engineering and gene expression analysis. Canopy Biosciences operates as a subsidiary of Bruker Corporation.

Kypha Inc. is a life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Through its innovative platform, Kypha provides rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. The company's approach facilitates testing across diverse settings, from home health care to clinical laboratories, ultimately aiming to improve patient outcomes by optimizing treatment strategies based on real-time immune insights. Since its incorporation in 2009, Kypha has attracted significant funding and built a strong network of scientific and clinical expertise to support its mission.

Atomation is a company that specializes in developing an Internet of Things (IoT) platform designed to connect existing legacy objects and assets to the internet. Founded in 2014 and headquartered in Saint Louis, Missouri, with origins in Tel Aviv, Israel, Atomation focuses on transforming data gathered from sensors into actionable insights. Its platform supports various sectors, including agriculture, medical, industrial, and logistics, by enabling devices to interact, analyze information, and make real-time decisions. Atomation offers both software and hardware development kits, providing businesses with affordable and straightforward solutions to enhance their operations and optimize their performance.

Plastomics Inc. is a biotechnology company specializing in chloroplast genetic engineering to enhance crop performance. Founded in 2016 and based in St. Louis, Missouri, the company focuses on gene stacking and rapid breeding to improve yield production and nutritional quality. Its innovative technology platform allows for the precise insertion of beneficial traits into the chloroplasts of plant cells, facilitating the development of more effective biotech crops. This approach not only addresses current industry challenges but also eliminates cross-pollination, enabling clients to achieve trait expression in plants more reliably. Additionally, Plastomics' unique method of maternal inheritance streamlines breeding timelines and reduces costs, making it a valuable partner for seed companies in the agricultural sector.

SentiAR, Inc. is a digital health company based in St. Louis, Missouri, specializing in 3D augmented reality solutions for interventional medical procedures. Founded in 2017 as a spin-off from Washington University, SentiAR has developed a platform that offers real-time holographic visualization of patients' anatomical structures and catheter locations. This technology integrates data from CT, MRI, and real-time mapping systems to create a controllable 3D holographic interface. The platform aims to enhance the delivery of care by allowing clinicians to visualize complex cardiac anatomy directly over the patient, thereby improving the treatment of cardiac arrhythmias during catheterization procedures. SentiAR is in the process of preparing its platform for submission to the FDA.

CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.

S4 is a technology service company that provides risk management solutions to ensure food production. It also develops index-based coverage to transfer the agriculture industry's volatilities to the financial markets, through OTC-derivatives contracts. The company offers products and services are used by a broad range of customers including large growers, crop protection and seeds suppliers, crop insurance providers, banking, and commodity exchanges. S4 integrates the harvest information with a planting plan, seed density, and soil analysis. They had developed a decision-making geo-referenced platform for the agricultural producer. They seek to improve the decision-making process in complex environments to collaborate in the global challenge of generating quality food for humanity. S4 was founded on 2011 and is headquartered in Buenos Aires, Argentina.

MedAware Solutions, Inc. is a healthcare communication technology company based in St. Louis, Missouri, founded in 2014. The company offers mViva, a comprehensive platform designed to facilitate care coordination among healthcare teams, payers, patients, and their families. This platform provides tools for real-time communication and collaboration throughout the continuum of care, allowing multi-disciplinary teams to engage in patient-centric discussions. It also enables patients and care teams to securely capture and share data in a HIPAA-compliant environment. By optimizing clinical resources and enhancing healthcare outcomes, MedAware Solutions aims to improve the overall patient experience while reducing costs in healthcare delivery.

Accuronix Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for pancreatic cancer. Founded in 2015 and based in the United States, the company employs a unique drug targeting technology that selectively targets Sigma-2 receptors, which are overexpressed on cancer cells. This approach aims to enhance the effectiveness of cancer treatment while minimizing toxicity risks for patients. Through its commitment to advancing oncology therapies, Accuronix Therapeutics seeks to address critical challenges in cancer care.

Edison Agrosciences, Inc. is an agricultural biotechnology company based in Durham, North Carolina, focused on developing innovative solutions for producing plant-based industrial materials. Founded in 2013, the company primarily aims to create alternative rubber crops for various applications, including consumer, medical, and industrial products. Edison employs advanced computational breeding and agronomic techniques to enhance rubber concentration in underutilized plant parts, thereby improving yield per acre. The company is building a robust intellectual property portfolio and forming strategic partnerships to support the validation of its crop and product innovations. With a leadership team experienced in the industry, Edison Agrosciences is committed to providing sustainable biomaterials through its agricultural practices.

S4 is a technology service company that provides risk management solutions to ensure food production. It also develops index-based coverage to transfer the agriculture industry's volatilities to the financial markets, through OTC-derivatives contracts. The company offers products and services are used by a broad range of customers including large growers, crop protection and seeds suppliers, crop insurance providers, banking, and commodity exchanges. S4 integrates the harvest information with a planting plan, seed density, and soil analysis. They had developed a decision-making geo-referenced platform for the agricultural producer. They seek to improve the decision-making process in complex environments to collaborate in the global challenge of generating quality food for humanity. S4 was founded on 2011 and is headquartered in Buenos Aires, Argentina.

Nitrogenics is a plant biotechnology company providing research analysis on nitrogen fixation in crop plants. Nitrogenics' services include data related to plant enzymes that are inserted in the genome of tobacco, enabling researchers to get to research on plants that absorbs nitrogen directly from the atmosphere, rather than from fertilized soil.

Antegrin Therapeutics, LLC, is a drug discovery and development company focused on the development of novel therapies for fibrotic diseases. Our lead program aims to develop a treatment for idiopathic pulmonary fibrosis, a progressive, life-threatening condition that currently has no FDA-approved medication.

MedSocket offers a clinical decision support system aimed at enhancing the efficiency and quality of patient care. The company has developed a patented 1-Click Decision Support (1-CDS) system and a medical search engine known as 1-Search, both designed by clinicians to address their specific needs. These technologies facilitate quick and easy access to evidence-based information for busy healthcare providers, thereby aiming to improve healthcare decisions, reduce errors, and enhance patient outcomes. Successful pilots of these systems at the University of Missouri Health System have demonstrated their potential to decrease healthcare costs and improve the overall efficiency of patient consultations. Founded in 2012 by Dr. Karl Kochendorfer, who recognized the necessity for immediate information access in clinical settings, MedSocket combines expertise in business and information science to refine clinical decision-making processes.

Euclises Pharmaceuticals, Inc. is engaged in the research, development, and commercialization of innovative medicines targeting inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company focuses on creating novel pain and cancer medications that promise enhanced safety profiles compared to current therapies. The firm is built on pioneering inventions by Dr. John Talley, a renowned medicinal chemist known for developing Celebrex among other approved drugs. Euclises aims to introduce new compounds that provide improved efficacy and safety, positioning itself as a leader in the pharmaceutical industry. The company operates from the BioGenerator Accelerator Labs, where it continues to advance its research initiatives.

Cofactor Genomics is a biotechnology company that specializes in predictive immune modeling and RNA sequencing. By advancing precision medicine, Cofactor aims to address existing barriers in the healthcare sector, transitioning from single-analyte biomarkers to comprehensive multidimensional biomarkers through health expression models. The company operates one of the first CAP-certified clinical RNA sequencing laboratories, which enhances the efficiency and cost-effectiveness of clinical trials for their partners. Cofactor’s expertise encompasses molecular biology, informatics, and database management, allowing them to provide high-quality services tailored to the needs of the healthcare and pharmaceutical industries. Their focus on RNA biomarkers associated with responses to targeted therapeutics supports the commercialization of clinical diagnostic assays for oncologic, immunologic, and neurodegenerative diseases, ultimately contributing to medical research and improved patient outcomes.

Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, founded in 2010. The company specializes in rational drug design, focusing on mechanistically novel kinase inhibitors aimed at addressing unmet medical needs in cancer and chronic inflammatory diseases. Its KINect technology platform is pivotal for identifying and developing new protein kinase drugs that target crucial enzymes involved in cancer growth, survival, and metastasis, as well as in modulating chronic inflammation. Unlike many competitors, Confluence Life Sciences explores novel binding sites on challenging kinase targets and previously un-targeted kinases. The company is driven by a team of experts with significant pharmaceutical experience, allowing it to pursue innovative strategies beyond traditional industry focus. To enhance its business potential, Confluence Life Sciences is also establishing scientific and business collaborations, fostering a pipeline strategy of discovery, development, and partnership. As of August 2017, it operates as a subsidiary of Aclaris Life Sciences, Inc.

GeneriCo, LLC is a pharmaceutical company that specializes in the development and marketing of generic drugs. Founded in 2013 and headquartered in Saint Louis, Missouri, with additional offices in Bengaluru, Italy, and South Korea, GeneriCo focuses on niche generic pharmaceuticals that are often overlooked by larger competitors. The company targets foundational medicines in key therapeutic areas, including cardiovascular health, pain management, central nervous system disorders, oncology, and aging-related conditions. GeneriCo distinguishes itself through its expertise in complex formulations and embedded drug delivery technologies, addressing market needs that are typically neglected by mid-sized and large generic firms. The company's global reach enables it to serve a diverse customer base.

NeuroLutions Inc. is a company based in St. Louis, Missouri, focused on developing brain-computer interface (BCI) devices aimed at restoring functions for patients disabled due to neurological injuries, particularly stroke survivors. Founded in 2007, NeuroLutions employs non-invasive electroencephalography (EEG) technology to capture brain activity without the need for implanted electrodes. The EEG data is wirelessly transmitted to a tablet, where it is analyzed to interpret the patient's intended muscle movements. This innovative approach enables users to facilitate muscle re-education and helps maintain or improve their range of motion, thereby enhancing rehabilitation outcomes for individuals with movement impairments.

SanusEO, LLC is a mobile health technology company based in St. Louis, Missouri, specializing in a text-based patient engagement platform (PEP) designed to enhance communication between patients and care teams. Founded in 2012, SanusEO's platform supports healthcare providers, chronic disease patients, and payers by delivering daily alerts and real-time data to care teams, facilitating both immediate and long-term intervention strategies. The platform is particularly effective for managing patients transitioning from hospital care and those newly diagnosed with chronic conditions. By utilizing mobile texting programs, SanusEO aims to modify patient behaviors related to medication adherence, vital monitoring, diet, physical activity, and overall communication with healthcare providers. The approach targets various chronic diseases, including diabetes and congestive heart failure, and offers multi-language capabilities to cater to diverse patient populations.

CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.

Euclises Pharmaceuticals, Inc. is engaged in the research, development, and commercialization of innovative medicines targeting inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company focuses on creating novel pain and cancer medications that promise enhanced safety profiles compared to current therapies. The firm is built on pioneering inventions by Dr. John Talley, a renowned medicinal chemist known for developing Celebrex among other approved drugs. Euclises aims to introduce new compounds that provide improved efficacy and safety, positioning itself as a leader in the pharmaceutical industry. The company operates from the BioGenerator Accelerator Labs, where it continues to advance its research initiatives.

CardiaLen, Inc. is a medical device company based in Minneapolis, Minnesota, specializing in the development of innovative therapies for atrial fibrillation and other heart arrhythmias. Founded in 2008, the company is focused on creating implantable, low-energy cardioverter devices that offer pain-free cardioversion therapies. These devices monitor the heartbeat and employ a proprietary series of low-energy pulses to restore normal heart rhythm while minimizing discomfort and preventing damage to heart tissue. By addressing significant unmet needs in the treatment of atrial fibrillation, CardiaLen aims to enhance patient outcomes and reduce reliance on high-energy defibrillation shocks.

RNAgri is a company based in St. Louis, Missouri, that specializes in innovative technology for producing ribonucleic acid (RNA). Founded in 2011, the company focuses on addressing the challenges associated with the large-scale production of exogenous RNA interference (RNAi) products. By utilizing a large-scale fermentation process, RNAgri enables farmers to enhance the protection and growth of their crops and livestock through the cost-efficient production of RNA. This technology aims to improve agricultural practices and contribute to more sustainable farming solutions.

SynerZ Medical, Inc. develops medical device for the treatment of obesity and type 2 diabetes. The company was incorporated in 2013 and is based in St. Louis, Missouri.

YourBevCo, LLC is a beverage device company focused on creating innovative consumer devices designed to eliminate problematic ingredients from beverages that may trigger allergic reactions or sensitivities. The company specializes in a portable, recyclable, single-use device specifically aimed at removing sulfites from wine. This technology addresses health concerns associated with sulfites, which can generate free radicals linked to cellular damage and increased disease risk. By enabling users to enjoy their drinks without compromising on appearance, aroma, or taste, YourBevCo aims to enhance the overall beverage experience while promoting safer consumption practices.

ImmunoPhotonics, Inc. is a biotechnology company focused on developing innovative immunotherapy treatments for cancer, specifically targeting metastatic solid tumors. Founded in 2008 and located in Columbia, Missouri, the company has created a proprietary drug product designed to function as a minimally invasive therapeutic cancer vaccine. This product is administered through intratumoral injection following tumor ablation, leveraging tumor-associated neoantigens to stimulate a systemic anti-tumor immune response. By transforming the process of tumor ablation into a therapeutic approach, ImmunoPhotonics aims to enhance treatment options for patients with late-stage metastatic cancers. The company has also established a strategic partnership with Veterinary Cancer Therapeutics, LLC to further its mission in cancer treatment.

Kypha Inc. is a life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Through its innovative platform, Kypha provides rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. The company's approach facilitates testing across diverse settings, from home health care to clinical laboratories, ultimately aiming to improve patient outcomes by optimizing treatment strategies based on real-time immune insights. Since its incorporation in 2009, Kypha has attracted significant funding and built a strong network of scientific and clinical expertise to support its mission.

Prostate Management Diagnostics creates tests and develops a fluid-based screening tool. It specializes in the fields of health diagnostics, medical, and healthcare. It was founded in 2014 and headquartered in San Francisco, California.

MedSocket offers a clinical decision support system aimed at enhancing the efficiency and quality of patient care. The company has developed a patented 1-Click Decision Support (1-CDS) system and a medical search engine known as 1-Search, both designed by clinicians to address their specific needs. These technologies facilitate quick and easy access to evidence-based information for busy healthcare providers, thereby aiming to improve healthcare decisions, reduce errors, and enhance patient outcomes. Successful pilots of these systems at the University of Missouri Health System have demonstrated their potential to decrease healthcare costs and improve the overall efficiency of patient consultations. Founded in 2012 by Dr. Karl Kochendorfer, who recognized the necessity for immediate information access in clinical settings, MedSocket combines expertise in business and information science to refine clinical decision-making processes.

Euclises Pharmaceuticals, Inc. is engaged in the research, development, and commercialization of innovative medicines targeting inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company focuses on creating novel pain and cancer medications that promise enhanced safety profiles compared to current therapies. The firm is built on pioneering inventions by Dr. John Talley, a renowned medicinal chemist known for developing Celebrex among other approved drugs. Euclises aims to introduce new compounds that provide improved efficacy and safety, positioning itself as a leader in the pharmaceutical industry. The company operates from the BioGenerator Accelerator Labs, where it continues to advance its research initiatives.

ImmunoPhotonics, Inc. is a biotechnology company focused on developing innovative immunotherapy treatments for cancer, specifically targeting metastatic solid tumors. Founded in 2008 and located in Columbia, Missouri, the company has created a proprietary drug product designed to function as a minimally invasive therapeutic cancer vaccine. This product is administered through intratumoral injection following tumor ablation, leveraging tumor-associated neoantigens to stimulate a systemic anti-tumor immune response. By transforming the process of tumor ablation into a therapeutic approach, ImmunoPhotonics aims to enhance treatment options for patients with late-stage metastatic cancers. The company has also established a strategic partnership with Veterinary Cancer Therapeutics, LLC to further its mission in cancer treatment.

Confluence gathers, filters, combines and presents the pharmaceutical intelligence you need. It turns manual into automatic, risk into reliability and wait into wow. With Confluence you start where it counts: crucial planning and decision-making. Skip the assembly, start with Confluence.

Benson Hill is an agricultural technology company that specializes in crop improvement and soy protein innovation. The company focuses on unlocking the natural genetic diversity of plants to develop healthier, more sustainable food and ingredients. Its proprietary CropOS platform leverages machine learning and big data alongside traditional breeding techniques to streamline and expedite the product development process. Benson Hill operates a Crop Accelerator designed for rapid prototyping and is actively developing a seed portfolio that includes protein ingredients, aquaculture, specialty animal feed, and vegetable oils. The company generates revenue from both proprietary and non-proprietary product categories, with proprietary revenue stemming from the sale of its unique bean varieties.

Tansna Therapeutics, Inc. is a drug discovery and development company based in St. Louis, Missouri, founded in 2010. The company specializes in creating and commercializing oral drugs aimed at treating epilepsy and other central nervous system disorders. Its primary focus is on developing novel oral anticonvulsant agents designed to effectively reduce seizure frequency in patients with epilepsy. By providing safe and innovative treatment options, Tansna Therapeutics aims to enhance the quality of care for individuals suffering from these debilitating conditions.

BacterioScan, Inc. is a medical device company based in St. Louis, Missouri, focused on diagnosing and treating infectious diseases. The company has developed the 216Dx UTI System, which detects bacteria indicative of urinary tract infections (UTIs) in clinical urine samples and helps identify suitable antibiotic treatments. Additionally, BacterioScan offers the 216R Antibiotic Susceptibility Testing System, designed to detect bacterial infections, assess antibiotic resistance, and provide clinicians with tailored antimicrobial resistance profiles. Its precision bench-top systems facilitate rapid detection and real-time quantification of microbial growth, significantly enhancing laboratory efficiency compared to traditional plating methods. This innovative approach not only aids clinicians in personalizing patient care but also supports researchers in accelerating the development of new antibiotics. BacterioScan's technology aims to improve the quality of antibiotic therapy and mitigate the risks associated with antibiotic resistance.

GeneriCo, LLC is a pharmaceutical company that specializes in the development and marketing of generic drugs. Founded in 2013 and headquartered in Saint Louis, Missouri, with additional offices in Bengaluru, Italy, and South Korea, GeneriCo focuses on niche generic pharmaceuticals that are often overlooked by larger competitors. The company targets foundational medicines in key therapeutic areas, including cardiovascular health, pain management, central nervous system disorders, oncology, and aging-related conditions. GeneriCo distinguishes itself through its expertise in complex formulations and embedded drug delivery technologies, addressing market needs that are typically neglected by mid-sized and large generic firms. The company's global reach enables it to serve a diverse customer base.

Adarza BioSystems is an early-stage medical diagnostics company based in St. Louis, Missouri, founded in 2008. The company specializes in developing a rapid and label-free biological assay platform that measures clinical and point-of-care samples. This innovative platform employs diagnostic arrayed imaging reflectometry (AIR) to enable the simultaneous detection of hundreds of analytes from a single drop of fluid, allowing healthcare professionals to conduct sophisticated tests with high sensitivity and specificity. By significantly reducing the time required for testing, Adarza BioSystems aims to enhance diagnostic capabilities in various healthcare settings.

Antegrin Therapeutics, LLC, is a drug discovery and development company focused on the development of novel therapies for fibrotic diseases. Our lead program aims to develop a treatment for idiopathic pulmonary fibrosis, a progressive, life-threatening condition that currently has no FDA-approved medication.

Indalo Therapeutics is a preclinical-stage biotechnology company focused on developing innovative therapies for patients afflicted by fibrotic diseases. Founded on significant scientific advancements, the company leverages deep insights into the molecular mechanisms that drive abnormal scarring. By assembling a skilled team of pharmaceutical scientists and industry executives, Indalo aims to address critical unmet medical needs in the field of fibrosis. Its therapeutic approach seeks to not only halt but also potentially reverse the progression of fibrotic conditions, ultimately improving the quality of life for affected individuals.

MediBeacon Inc. is a medical technology company specializing in real-time kidney function monitoring solutions. Founded in 2012 and based in St. Louis, Missouri, the company develops innovative optical diagnostic systems aimed at enhancing patient care. Its flagship product, the NIC-Kidney device, allows for the monitoring of glomerular filtration rate (mGFR) in preclinical settings. MediBeacon also offers a renal function system that combines an optical skin sensor with a proprietary fluorescent agent, enabling continuous real-time monitoring of kidney function. This technology is particularly beneficial in intensive care units and operating rooms, where it helps clinicians optimize patient outcomes and dosing strategies. The company has a robust intellectual property portfolio that includes additional product concepts for physiological monitoring and imaging of pathological diseases, positioning it as a leader in nephrology and optical diagnostics.

Tansna Therapeutics, Inc. is a drug discovery and development company based in St. Louis, Missouri, founded in 2010. The company specializes in creating and commercializing oral drugs aimed at treating epilepsy and other central nervous system disorders. Its primary focus is on developing novel oral anticonvulsant agents designed to effectively reduce seizure frequency in patients with epilepsy. By providing safe and innovative treatment options, Tansna Therapeutics aims to enhance the quality of care for individuals suffering from these debilitating conditions.

Benson Hill is an agricultural technology company that specializes in crop improvement and soy protein innovation. The company focuses on unlocking the natural genetic diversity of plants to develop healthier, more sustainable food and ingredients. Its proprietary CropOS platform leverages machine learning and big data alongside traditional breeding techniques to streamline and expedite the product development process. Benson Hill operates a Crop Accelerator designed for rapid prototyping and is actively developing a seed portfolio that includes protein ingredients, aquaculture, specialty animal feed, and vegetable oils. The company generates revenue from both proprietary and non-proprietary product categories, with proprietary revenue stemming from the sale of its unique bean varieties.

Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, founded in 2010. The company specializes in rational drug design, focusing on mechanistically novel kinase inhibitors aimed at addressing unmet medical needs in cancer and chronic inflammatory diseases. Its KINect technology platform is pivotal for identifying and developing new protein kinase drugs that target crucial enzymes involved in cancer growth, survival, and metastasis, as well as in modulating chronic inflammation. Unlike many competitors, Confluence Life Sciences explores novel binding sites on challenging kinase targets and previously un-targeted kinases. The company is driven by a team of experts with significant pharmaceutical experience, allowing it to pursue innovative strategies beyond traditional industry focus. To enhance its business potential, Confluence Life Sciences is also establishing scientific and business collaborations, fostering a pipeline strategy of discovery, development, and partnership. As of August 2017, it operates as a subsidiary of Aclaris Life Sciences, Inc.

Euphrates Vascular is a medical technology company based in St. Louis, Missouri, that focuses on innovative solutions for the treatment of stroke, heart disease, and other conditions. The company has developed a proprietary magnetically-enhanced diffusion (MED) system that utilizes magnet-based technology to dissolve blood clots more rapidly than existing treatment options. This system aims to improve the efficacy of FDA-approved clot-busting medications, potentially reducing mortality rates associated with stroke and cardiovascular diseases. In addition to the MED system, Euphrates Vascular offers MED MicroBeads, which are designed to deliver therapeutic agents directly to clots during thrombolysis therapy, and a touch screen-operated MED Workstation. Founded by physicists with extensive experience in medical technology, the company continues to advance its pioneering approaches in the healthcare sector, attracting interest from investors and media alike.

Apertus Pharmaceuticals is a manufacturer of Active Pharmaceutical Ingredients (APIs) serving dosage form manufacturing companies in the pharmaceutical industry. The company specializes in both controlled and non-controlled substance APIs, along with offering intellectual property services. Committed to high purity standards, Apertus Pharmaceuticals incorporates the principles of Green Chemistry as defined by the FDA into its operations. The leadership team includes CEO Rick Ryan, Ph.D., and CSO David Gindelberger, Ph.D.

Kypha Inc. is a life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Through its innovative platform, Kypha provides rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. The company's approach facilitates testing across diverse settings, from home health care to clinical laboratories, ultimately aiming to improve patient outcomes by optimizing treatment strategies based on real-time immune insights. Since its incorporation in 2009, Kypha has attracted significant funding and built a strong network of scientific and clinical expertise to support its mission.

Companion Pharma is an animal health product development company that will develop innovative new formulations of drugs for use under prescription in companion animals. Companion will specifically target companion animal disease indications that have a high unmet treatment need and will provide 'pet friendly' drugs that are proven to work safely in the target species, are formulated in a way to provide ease of administration and are available in doses that meet the needs of the highly variable weight profile of companion animal pets.

Array Bridge specializes in providing high-quality products and services tailored for the pharmaceutical and biotechnology sectors. The company offers a range of products, including antibody arrays designed for three-dimensional conformational comparability analysis of biosimilars and antibody-drug conjugates, as well as ELISA kits for detecting host cell proteins from various biological sources. Additionally, Array Bridge provides services that encompass antibody production, method qualification and validation for binding-based bioassays, and comprehensive analyses of process-related impurities, including 1-D and 2-D gel studies and Western Blot analysis. The firm is committed to supporting drug development efforts by helping clients detect contaminants such as host cell proteins and residual DNA.

RNAgri is a company based in St. Louis, Missouri, that specializes in innovative technology for producing ribonucleic acid (RNA). Founded in 2011, the company focuses on addressing the challenges associated with the large-scale production of exogenous RNA interference (RNAi) products. By utilizing a large-scale fermentation process, RNAgri enables farmers to enhance the protection and growth of their crops and livestock through the cost-efficient production of RNA. This technology aims to improve agricultural practices and contribute to more sustainable farming solutions.

ARTA Bioscience, Inc is developing new therapeutics for prostate cancer and inflammatory diseases. Current treatments for prostate cancer are insufficient and the disease is the second leading cause of cancer deaths among American men. ARTA's technology involves an entirely different approach to combating disease compared to traditional treatments. In addition to prostate cancer, the company's technologies may be used to target other important proteins in the nuclear receptor class. The company has established operations at the BioGenerator Accelerator Labs. ARTA's technology was developed by Dr. Marc Diamond at Washington University.

Mobius Therapeutics, LLC is a developer of sterile injectable pharmaceutical products focused on ophthalmic applications in the United States. Founded in 2006 and based in St. Louis, Missouri, the company offers Mitosol, a kit that provides a safe method for reconstituting and transferring mitomycin, an antifibrotic agent used in glaucoma, refractive, and corneal surgeries. Additionally, Mobius Therapeutics produces Amphadase, a hyaluronidase injection. The company serves ophthalmologists and their patients by providing products that enhance surgical outcomes and patient care. Its offerings are available for purchase online, and the company is actively pursuing regulatory approval for its products, with further developments in the pipeline.

Array Bridge specializes in providing high-quality products and services tailored for the pharmaceutical and biotechnology sectors. The company offers a range of products, including antibody arrays designed for three-dimensional conformational comparability analysis of biosimilars and antibody-drug conjugates, as well as ELISA kits for detecting host cell proteins from various biological sources. Additionally, Array Bridge provides services that encompass antibody production, method qualification and validation for binding-based bioassays, and comprehensive analyses of process-related impurities, including 1-D and 2-D gel studies and Western Blot analysis. The firm is committed to supporting drug development efforts by helping clients detect contaminants such as host cell proteins and residual DNA.

Confluence Discovery Technologies is a contract research organization specializing in drug discovery, with a focus on developing kinase inhibitors for cancer and inflammatory diseases. The company offers a range of technical services, including mechanistic enzymology, target validation and characterization, screening and assay development, as well as biomarker development and measurement. With a foundation built on decades of experience from its founders, who were prominent leaders in Pfizer's Inflammation Research Unit, Confluence employs innovative methods to identify and develop clinical candidates targeting critical enzymes that regulate cancer growth and chronic inflammation. The organization is based at the BioGenerator Accelerator Labs, providing a conducive environment for advancing its research initiatives.

Euphrates Vascular is a medical technology company based in St. Louis, Missouri, that focuses on innovative solutions for the treatment of stroke, heart disease, and other conditions. The company has developed a proprietary magnetically-enhanced diffusion (MED) system that utilizes magnet-based technology to dissolve blood clots more rapidly than existing treatment options. This system aims to improve the efficacy of FDA-approved clot-busting medications, potentially reducing mortality rates associated with stroke and cardiovascular diseases. In addition to the MED system, Euphrates Vascular offers MED MicroBeads, which are designed to deliver therapeutic agents directly to clots during thrombolysis therapy, and a touch screen-operated MED Workstation. Founded by physicists with extensive experience in medical technology, the company continues to advance its pioneering approaches in the healthcare sector, attracting interest from investors and media alike.

PixelEXX Systems Inc. is a company specializing in the development of innovative imaging devices aimed at cancer diagnosis. Founded in 2008 and headquartered in Saint Louis, Missouri, the company focuses on creating advanced nanoarrays that capture molecular signals related to cellular activity. Their proprietary technology features novel nano resonant photodiodes that enhance sensitivity and allow the capture of both wavelength and polarization information without the need for additional components like microlenses or filters. This approach enables clients to optimize imaging and sensing capabilities while reducing size, weight, and power consumption.

APT Therapeutics is a biotechnology company based in St. Louis, Missouri, focused on developing innovative antiplatelet therapies. The company aims to transform human apyrase into a life-saving medicine through advanced techniques in protein engineering, protein informatics, and cheminformatics software. APT Therapeutics' therapies target critical medical conditions such as acute myocardial infarction, stroke, and complications arising from transplantation. By enhancing the effectiveness of these treatments, the company seeks to minimize damage to patients during heart attacks and improve their overall outcomes.